These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24816692)

  • 21. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
    Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
    BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.
    Abu-Raddad LJ; Sabatelli L; Achterberg JT; Sugimoto JD; Longini IM; Dye C; Halloran ME
    Proc Natl Acad Sci U S A; 2009 Aug; 106(33):13980-5. PubMed ID: 19666590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of tuberculosis infection in children.
    Hatzenbuehler LA; Starke JR
    Expert Rev Anti Infect Ther; 2018 Sep; 16(9):695-708. PubMed ID: 30132364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.
    Kendall EA; Azman AS; Cobelens FG; Dowdy DW
    PLoS One; 2017; 12(3):e0172748. PubMed ID: 28273116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of tuberculosis treatment length and adherence under different transmission intensities.
    Pinho ST; Rodrigues P; Andrade RF; Serra H; Lopes JS; Gomes MG
    Theor Popul Biol; 2015 Sep; 104():68-77. PubMed ID: 26163050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regimens of less than six months for treating tuberculosis.
    Gelband H
    Cochrane Database Syst Rev; 2000; 1999(2):CD001362. PubMed ID: 10796641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.
    Dookie N; Ngema SL; Perumal R; Naicker N; Padayatchi N; Naidoo K
    Clin Microbiol Rev; 2022 Dec; 35(4):e0018019. PubMed ID: 36200885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis.
    Vesga JF; Lienhardt C; Nsengiyumva P; Campbell JR; Oxlade O; den Boon S; Falzon D; Schwartzman K; Churchyard G; Arinaminpathy N
    BMC Med; 2022 May; 20(1):182. PubMed ID: 35581650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
    Velayutham B; Jawahar MS; Nair D; Navaneethapandian P; Ponnuraja C; Chandrasekaran K; Narayan Sivaramakrishnan G; Makesh Kumar M; Paul Kumaran P; Ramesh Kumar S; Baskaran D; Bella Devaleenal D; Sirasanambati DR; Vasantha M; Palaniyandi P; Ramachandran G; Uma Devi KR; Elizabeth Hannah L; Sekar G; Radhakrishnan A; Kalaiselvi D; Dhanalakshmi A; Thiruvalluvan E; Raja Sakthivel M; Mahilmaran A; Sridhar R; Jayabal L; Rathinam P; Angamuthu P; Soorappa Ponnusamy K; Venkatesan P; Natrajan M; Prasad Tripathy S; Swaminathan S
    Trop Med Int Health; 2020 Apr; 25(4):483-495. PubMed ID: 31944502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.
    Gomez GB; Dowdy DW; Bastos ML; Zwerling A; Sweeney S; Foster N; Trajman A; Islam MA; Kapiga S; Sinanovic E; Knight GM; White RG; Wells WA; Cobelens FG; Vassall A
    BMC Infect Dis; 2016 Dec; 16(1):726. PubMed ID: 27905897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach.
    Han WM; Mahikul W; Pouplin T; Lawpoolsri S; White LJ; Pan-Ngum W
    PLoS One; 2021; 16(3):e0248846. PubMed ID: 33770104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis.
    Reddy KP; Horsburgh CR; Wood R; Fields NF; Girouard MP; Costantini S; Hou T; Freedberg KA; Walensky RP
    Ann Am Thorac Soc; 2020 Feb; 17(2):202-211. PubMed ID: 31689133
    [No Abstract]   [Full Text] [Related]  

  • 40. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
    Rose DN
    Ann Intern Med; 1998 Nov; 129(10):779-86. PubMed ID: 9841583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.